Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck-Loomis B, Meng F, Yang JL, Tobi Y, Heller G, Ahn L, Hayes SA, Young RJ, Arcila ME, Berger M, Chaft JE, Ladanyi M, Riely GJ, Kris MG. Yu HA, et al. Among authors: tobi y. JAMA Oncol. 2020 Jul 1;6(7):1048-1054. doi: 10.1001/jamaoncol.2020.1260. JAMA Oncol. 2020. PMID: 32463456 Free PMC article. Clinical Trial.
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. Poels KE, et al. Among authors: tobi y. Nat Commun. 2021 Jun 17;12(1):3697. doi: 10.1038/s41467-021-23912-4. Nat Commun. 2021. PMID: 34140482 Free PMC article. Clinical Trial.
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
Choudhury NJ, Makhnin A, Tobi YY, Daly RM, Preeshagul IR, Iqbal AN, Ahn LS, Hayes SA, Heller G, Kris MG, Riely GJ, Yu HA. Choudhury NJ, et al. Among authors: tobi yy. JCO Precis Oncol. 2021 Apr 22;5:PO.21.00005. doi: 10.1200/PO.21.00005. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250398 Free PMC article. Clinical Trial.
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations.
Arbour KC, Manchado E, Bott MJ, Ahn L, Tobi Y, Ni AA, Yu HA, Shannon A, Ladanyi M, Perron V, Ginsberg MS, Johnson A, Holodny A, Kris MG, Rudin CM, Lito P, Rosen N, Lowe S, Riely GJ. Arbour KC, et al. Among authors: tobi y. JTO Clin Res Rep. 2021 Nov 23;3(1):100256. doi: 10.1016/j.jtocrr.2021.100256. eCollection 2022 Jan. JTO Clin Res Rep. 2021. PMID: 34984405 Free PMC article.
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. Poels KE, et al. Among authors: tobi y. Nat Commun. 2022 Sep 23;13(1):5579. doi: 10.1038/s41467-022-33355-0. Nat Commun. 2022. PMID: 36151107 Free PMC article. No abstract available.
The Innate Immune System Surveillance Biomarker p87 in African Americans and Caucasians with Small High-Grade Dysplastic Adenoma [SHiGDA] and Right-Sided JAK3 Colon Mutations May Explain the Presence of Multiple Cancers Revealing an Important Minority of Patients with JAK3 Mutations and Colorectal Neoplasia.
Tobi M, Zhao X, Rodriquez R, Tobi YY, Ganguly T, Kuhn D, McVicker B, Lawson MJ, Lieb J 2nd, Lopes JL. Tobi M, et al. Among authors: tobi yy. Gastrointest Disord (Basel). 2024 Jun 7;6(2):497-512. doi: 10.3390/gidisord6020034. Gastrointest Disord (Basel). 2024. PMID: 39507544 Free PMC article.
The Non-Invasive Prediction of Colorectal Neoplasia (NIPCON) Study 1995-2022: A Comparison of Guaiac-Based Fecal Occult Blood Test (FOBT) and an Anti-Adenoma Antibody, Adnab-9.
Tobi M, Antaki F, Rambus MA, Yang YX, Kaplan D, Rodriguez R, Maliakkal B, Majumdar A, Demian E, Tobi YY, Sochacki P, Ehrinpreis M, Lawson MG, McVicker B. Tobi M, et al. Among authors: tobi yy. Int J Mol Sci. 2023 Dec 8;24(24):17257. doi: 10.3390/ijms242417257. Int J Mol Sci. 2023. PMID: 38139086 Free PMC article.
In the SARS-CoV-2 Pandora Pandemic: Can the Stance of Premorbid Intestinal Innate Immune System as Measured by Fecal Adnab-9 Binding of p87:Blood Ferritin, Yielding the FERAD Ratio, Predict COVID-19 Susceptibility and Survival in a Prospective Population Database?
Tobi M, Bluth MH, Rossi NF, Demian E, Talwar H, Tobi YY, Sochacki P, Levi E, Lawson M, McVicker B. Tobi M, et al. Among authors: tobi yy. Int J Mol Sci. 2023 Apr 19;24(8):7536. doi: 10.3390/ijms24087536. Int J Mol Sci. 2023. PMID: 37108697 Free PMC article.
Comparison of salivary hemoglobin measurements for periodontitis screening.
Okada A, Nomura Y, Sogabe K, Oku H, Sato Gillbreath A, Hino F, Hayashi H, Yoshino H, Utsunomiya H, Suzuki K, Koresawa K, Koba K, Uetani K, Kotoh M, Nishitsuji N, Akutsu S, Nakasone T, Tobi Y, Fukuzawa Y, Yabuki Y, Naono Y, Yajima M, Shimizu K, Hanada N. Okada A, et al. Among authors: tobi y. J Oral Sci. 2017;59(1):63-69. doi: 10.2334/josnusd.16-0204. J Oral Sci. 2017. PMID: 28367900 Free article.